Tags : Biosimilar


Bioeq Collaborates with Teva to Commercialize FYB201 (biosimilar, ranibizumab)

Shots: Polpharma reported that its JV with Santo Holding, Bioeq has concluded a commercial partnership with Teva for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis) in the EU, Canada, Israel, and New Zealand The agreement complements an existing agreement concluded with Coherus for the commercialization of the biosimilar in the US FYB201 was […]Read More


Teva Signs an Exclusive Commercialization Agreement with Bioeq for FYB201

Shots: The companies collaborated to commercialize Bioeq’s FYB201 (biosimilar referencing Lucentis) in the EU, Canada, Israel & New Zealand Bioeq will be responsible for the development, registration, and supply of the biosimilar while Teva will be responsible for commercializing the product. The companies will share revenue from the commercialization of the biosimilar The collaboration will […]Read More

Biosimilars Clinical Trials

Celltrion Presents Real-World Data of Truxima (biosimilar, rituximab) for Diffuse

Shots: The new data from the post-approval study evaluates the effectiveness & safety of Truxima (CT-P10) in patients with DLBCL in a real-world setting across Europe Results: @30mos. post-index, 67% had not experienced disease progression with OS (74%), three-quarters patients achieved complete or partial response @30mos., well tolerated with AEs while response rates, survival rates […]Read More